Education
About Us
Working with TipRanks
Follow Us
Dyadic International (DYAI)
NASDAQ:DYAI
Top Page
Dyadic International
(NASDAQ:DYAI)
Select Model
Select Model
Rating:46Neutral
Price Target:―
Dyadic International's overall score reflects significant financial challenges, notably ongoing losses and negative cash flows. While strategic partnerships and revenue growth are positive, they are offset by high leverage and operational inefficiencies. The stock's technical indicators suggest weak momentum, and its valuation remains unattractive due to unprofitability. The earnings call provides some optimism about future growth, but near-term challenges persist.
Dyadic International (DYAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$41.53M
Dividend YieldN/A
Average Volume (3M)139.23K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth129.20%
EPS Growth30.36%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding36,187,798
10 Day Avg. Volume150,632
30 Day Avg. Volume139,227
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue6.84
Enterprise Value/Gross Profit9.09
Enterprise Value/Ebitda-5.41
Forecast
1Y Price Target
$5.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Dyadic International Business Overview & Revenue Model
Company DescriptionDyadic International (DYAI) is a biotechnology company that focuses on developing and commercializing biopharmaceuticals and bio-based products using its proprietary C1 gene expression platform. This platform is designed to enable the efficient and cost-effective production of biologic products, including vaccines, antibodies, and enzymes, across various industries such as healthcare, agriculture, and industrial enzymes.
How the Company Makes MoneyDyadic International generates revenue through licensing its C1 gene expression technology to pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties based on the commercial success of products developed using the C1 platform. The company also engages in research and development collaborations, where it provides its expertise and technology in exchange for funding. Additionally, Dyadic may generate revenue through the sale of its proprietary enzymes and other bio-based products developed using its platform.
Dyadic International Earnings Call Summary
Earnings Call Date:Aug 13, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call conveyed a positive outlook with significant revenue growth, strategic rebranding, strong partnerships, and financial positioning to support future product launches. However, the company still faces challenges with a notable net loss and uncertain cash burn rate.Q2-2025 Updates
Positive Updates
Revenue Growth
Total revenue for the quarter increased to $967,000, up from $386,000 in the same period a year ago, driven by milestone revenue and grant revenue.
Strategic Transformation
Dyadic transitioned from a technology-focused R&D company to a market-facing revenue-driven biotechnology business, rebranding as Dyadic Applied BioSolutions.
Equity Raise
Dyadic strengthened its balance sheet with a $5.3 million equity raise to fund product development and commercialization efforts.
Partnerships and Milestones
Received $1 million in milestone payments from Proliant Health & Biologics and $250,000 from Inzymes for productivity gains. A $1.5 million milestone was triggered by the Gates Foundation grant.
Product Advancements
Advancements in recombinant human albumin, transferrin, and FGFs, with commercial launches and sampling underway. RNase-Free DNase1 production scaled up, with sampling and commercial discussions ongoing.
Negative Updates
Net Loss
Net loss for the quarter was $1,794,000 or $0.06 per share, though this was a decrease from the $2,045,000 or $0.07 per share loss a year ago.
Cash Position
Cash and equivalents decreased to $7.3 million as of June 30, 2025, from $9.3 million at the end of 2024.
Uncertain Cash Burn Rate
Future cash burn rate remains uncertain due to variability in anticipated product revenues and expenses.
Company Guidance
During Dyadic International's Q2 2025 conference call, significant guidance was provided regarding the company's strategic and financial direction. The company reported a total revenue increase to $967,000, a substantial rise from $386,000 in the same period a year ago, driven by milestone and grant revenues. Operational expenses were carefully managed, with a decrease in G&A expenses to $1,437,000 from $1,608,000 the previous year, reflecting reductions in several administrative costs. The net loss for the quarter was reduced to $1,794,000 or $0.06 per share, compared to $2,045,000 or $0.07 per share last year. Dyadic announced a $5.3 million equity raise, strengthening its balance sheet to support late-stage product development and upcoming launches. The company has focused its strategy on high-growth, nontherapeutic markets with its proprietary platforms, C1 and Dapibus, which enable efficient and scalable animal-free protein production. Looking forward, Dyadic anticipates further revenue growth with upcoming milestones and product sales, aiming to achieve cash flow positivity by the end of 2026.Dyadic International Financial Statement Overview
Summary
Dyadic International faces significant financial challenges, including ongoing losses and negative cash flows. Despite some revenue growth, the company's high leverage and operational inefficiencies pose risks. However, maintaining liquidity through cash reserves is a positive aspect.Income Statement
Dyadic International has shown some revenue growth over the years, with a 20.6% increase from 2023 to 2024. However, the company has consistently reported negative net income, leading to negative net profit margins. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.30
Negative
Balance Sheet
The company's debt-to-equity ratio has increased significantly in 2024, indicating higher leverage and potential financial risk. The equity ratio has decreased over the years, reflecting a lower proportion of equity financing. However, the company maintains a reasonable amount of cash and short-term investments, providing some liquidity cushion.45
Neutral
Cash Flow
Operating cash flows have been negative, reflecting challenges in generating cash from operations. Free cash flow has also remained negative, though there was a notable decrease in the cash outflow in 2024 compared to previous years. The operating cash flow to net income ratio indicates a gap between reported earnings and cash generation, which may concern investors.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.14M | 3.50M | 2.90M | 2.93M | 2.40M | 1.60M |
| Gross Profit | 3.11M | 2.30M | 922.96K | 807.11K | 459.39K | 176.99K |
| EBITDA | -5.23M | -5.38M | -8.19M | -10.07M | -11.14M | -10.19M |
| Net Income | -5.58M | -5.81M | -6.80M | -9.74M | -13.07M | -9.33M |
Balance Sheet | ||||||
| Total Assets | 8.14M | 9.93M | 8.22M | 13.71M | 21.30M | 30.07M |
| Cash, Cash Equivalents and Short-Term Investments | 6.57M | 9.26M | 7.26M | 12.64M | 20.26M | 29.09M |
| Total Debt | 5.06M | 5.07M | 136.93K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 8.67M | 7.46M | 2.34M | 2.63M | 2.91M | 1.63M |
| Stockholders Equity | -529.70K | 2.47M | 5.88M | 11.09M | 18.39M | 28.45M |
Cash Flow | ||||||
| Free Cash Flow | -2.98M | -3.97M | -6.73M | -8.08M | -11.28M | -6.57M |
| Operating Cash Flow | -2.98M | -3.97M | -6.73M | -8.08M | -11.28M | -6.57M |
| Investing Cash Flow | 771.78K | -1.88M | 7.45M | -2.37M | 5.22M | 22.12M |
| Financing Cash Flow | 48.50K | 5.85M | 0.00 | 543.59K | 1.23M | 255.47K |
Dyadic International Technical Analysis
Positive
1.10
Price Trends
0.97
Positive
0.98
Positive
1.23
Negative
Market Momentum
0.05
Negative
60.23
Neutral
81.42
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYAI, the sentiment is Positive. The current price of 1.1 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 0.97, and below the 200-day MA of 1.23, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 60.23 is Neutral, neither overbought nor oversold. The STOCH value of 81.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DYAI.
Dyadic International Risk Analysis
Dyadic International disclosed 41 risk factors in its most recent earnings report. Dyadic International reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dyadic International Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | 106.36M | -1.93 | ― | ― | -67.67% | -390.60% | |
47 Neutral | 49.23M | -0.70 | -46.97% | ― | ― | -5.42% | |
46 Neutral | $41.53M | ― | -422.64% | ― | 129.20% | 30.36% | |
46 Neutral | 60.06M | -0.71 | -655.11% | ― | 4.45% | 45.19% | |
42 Neutral | 15.94M | -0.46 | ― | ― | 77.78% | 84.08% | |
34 Underperform | 34.16M | -1.00 | ― | ― | ― | 44.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
DYAI
Dyadic International
1.10
0.00
0.00%
CLSD
Clearside Biomedical
4.04
-13.36
-76.78%
CLGN
Collplant Holdings
3.14
-1.79
-36.31%
RVPH
Reviva Pharmaceuticals Holdings
0.30
-1.05
-77.78%
GBIO
Generation Bio
6.00
-18.30
-75.31%
RANI
Rani Therapeutics Holdings
0.48
-1.68
-77.78%
Dyadic International Corporate Events
Executive/Board ChangesShareholder Meetings
Dyadic International Director Arindam Bose Announces Retirement
Neutral
Apr 29, 2025
On April 28, 2025, Arindam Bose announced his decision to retire as a director of Dyadic International, Inc., effective at the company’s annual meeting on June 20, 2025. His retirement is not due to any disagreements with the company regarding its operations, policies, or practices.
Spark’s Take on DYAI Stock
According to Spark, TipRanks’ AI Analyst, DYAI is a Neutral.
Dyadic International’s overall score reflects significant financial challenges, notably ongoing losses and negative cash flows. While strategic partnerships and revenue growth are positive, they are offset by high leverage and operational inefficiencies. The stock’s technical indicators suggest weak momentum, and its valuation remains unattractive due to unprofitability. The earnings call provides some optimism about future growth, but near-term challenges persist.
To see Spark’s full report on DYAI stock, click here.
Private Placements and FinancingBusiness Operations and Strategy
Dyadic International Secures $4.5M for Vaccine Development
Positive
Mar 20, 2025
On March 20, 2025, Dyadic International announced a $4.5 million funding award from CEPI to accelerate the development of protein-based vaccines using its C1 fungus technology. The initiative aims to reduce vaccine development timelines significantly, potentially enabling vaccines to enter Phase 1 trials in just 35 days compared to the traditional four to six months. This approach could also lower production costs and increase accessibility, particularly in regions with less established manufacturing infrastructure, aligning with the global 100 Days Mission to expedite vaccine readiness against pandemic threats.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.